梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2015年年度报告「NYSE」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended December 31,2015ORTRANSI

2、TION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the transition period fromtoORSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934Date of event requiring this shell company report:Commission File number:001-16174TEVA PHARMACEUT

3、ICAL INDUSTRIES LIMITED(Exact name of Registrant as specified in its charter)Not Applicable(Translation of Registrants name into English)ISRAEL(Jurisdiction of incorporation or organization)5 Basel StreetP.O.Box 3190Petach Tikva 4951033,Israel(Address of principal executive offices)Eyal DeshehGroup

4、Executive Vice President,Chief Financial OfficerTeva Pharmaceutical Industries Limited5 Basel StreetP.O.Box 3190Petach Tikva 4951033,IsraelTel:972-3-914-8171Fax:972-3-914-8678(Name,telephone,e-mail and/or facsimile number and address of Company contact person)Securities registered or to be registere

5、d pursuant to Section 12(b)of the Act.Title of each className of each exchange on which registeredAmerican Depositary Shares,each representing one Ordinary ShareNew York Stock ExchangeSecurities registered or to be registered pursuant to Section 12(g)of the Act.None(Title of Class)Securities for whi

6、ch there is a reporting obligation pursuant to Section 15(d)of the Act.None(Title of Class)Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.907,663,041 Ordinary Shares781,355,149 American De